what phase is retatrutide in The numbers from Lilly's 3 trial dropped this week and I haven't been able to stop thinking about them. Not only as a doctor but as a long-term GLP-1 user Retatrutide Shows 28% Weight Loss

P EG ylation : Increasing the molecular size of the drug to slow enzymatic degradation

Serious but less common adverse effects include pancreatitis, gallbladder disease, acute kidney injury (particularly in the setting of dehydration from gastrointestinal symptoms), and hypoglycemia when used in combination with insulin or sulfonylureas

This dual-action mechanism offers a comprehensive approach to weight management

Notably, it integrates the most current evidence pertaining to novel domains, such as perioperative management, neuropsychiatric outcomes, and the innovation of multi-receptor agonists

The outcomes data drove it, and access plus adherence support is where clinical teams are still catching up

doi: 10.1016/j.molmet.2021.101180 209 KellyPMcCleanPLAckermannMKonerdingMAHolscherCMitchellCA